Key result
A novel simvastatin self-emulsifying drug delivery system reduced plasma total cholesterol by 0.55-fold compared to a reference aqueous suspension in rats over 21 days.
Why the study?
Does a self-emulsifying drug delivery system for simvastatin improve lipid-lowering pharmacodynamic effects compared to a standard aqueous suspension in hypercholesterolemic rats?
Does a self-emulsifying drug delivery system for simvastatin improve lipid-lowering pharmacodynamic effects compared to a standard aqueous suspension in hypercholesterolemic rats?
A self-emulsifying drug delivery system for simvastatin significantly improved its lipid-lowering pharmacodynamic effects in rats compared to a standard aqueous suspension.
Answers are grounded in this paper and cite their sources.
Preclinical enhancement of simvastatin delivery is hypothesis-generating; leaves open translation to human hypercholesterolemia therapy.
The objective of the present work was to formulate a self-emulsifying drug delivery system (SEDDS) for simvastatin, which is widely used in the treatment of hypercholesterolemia and dyslipidemia as an adjunct to diet. Simvastatin SEDDS were formulated using a 1:1 (V/V) mixture of diesters of caprylic/capric acids and polyglycolyzed glycerides with varying concentrations of polyoxy castor oil and C8/C10 mono-/diglycerides. The developed SEDDS were evaluated for turbidimetry, droplet size analysis, drug content and in vitro diffusion profiles. In vivo performance of the optimized formulation was evaluated in rats using pharmacodynamic marker parameters like plasma total cholesterol (CH), triglycerides (TG) and high-density lipoprotein (HDL-CH) for 21 days. SEDDS containing 9.1% (m/m) simvastatin and 23.0% (m/m) of each excipient showed minimum mean droplet size (124 nm) and optimal drug diffusion. This test formulation showed significant reduction in plasma CH and TG (around 5-fold and 4-fold, respectively), while HDL-CH concentration was markedly higher (2-fold) compared a reference simvastatin suspension formulation after oral administration for 21 days of study. Test formulation has shown enhanced pharmacodynamic performance compared to reference formulation in rats. The study illustrated the potential of simvastatin SEDDS for oral administration and its biopharmaceutic performance.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2007) studied Hypercholesterolemia (n=24). Simvastatin self-emulsifying drug delivery system (SEDDS) vs. Simvastatin aqueous suspension was evaluated on Plasma total cholesterol at 21 days (0.55-fold, p=<0.001). A novel simvastatin self-emulsifying drug delivery system reduced plasma total cholesterol by 0.55-fold compared to a reference aqueous suspension in rats over 21 days.
Synapse has enriched 10 related papers. Consider them for comparative context: